In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Faces Mounting Pressure on Shortcut Approval Pathway

Executive Summary

The FDA has recently come under fire by big pharma and big biotech. The issue: FDA's interpretation of a section of the Federal Food, Drug, and Cosmetic Act-505(b)(2)-which allows companies to rely on data other than their own to attain drug approval.
Advertisement

Related Content

Nothing Random About It: The State of Cancer Drug Development at FDA
Shadow FDA? Researchers Are Taking Approval Matters into their Own Hands
Flying Through FDA: Test Runs For Pilot 1
A Little Knowledge: The FDA's Public Approach to Safety
McClellan's Balancing Act: Yes to Generics, No to Imports & Price Controls
The Battle for IP
The Battle for IP
Pfizer v. Reddy: Drug Patents Under Fire
Pfizer v. Reddy: Drug Patents Under Fire
Biogenerics Are Coming and They're Not the Generics We Know

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

IV002337

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel